ARID2 and neoplasm: A genome‐scale CRISPR‐Cas9 screen to identify mechanisms of tumor cell resistance to killing by cytotoxic T cells identified the loss of over 100 genes, including PBRM1, ARID2, and BRD7, as sensitizing events to T cell‐mediated killing [54].